Ampio Pharmaceuticals Files FormRW To Terminate That Certain At The Marketing Offering Agreement, Dated September 18, 2023
Portfolio Pulse from Benzinga Newsdesk
Ampio Pharmaceuticals, Inc. (AMPE) has notified H.C. Wainwright & Co., LLC of its decision to terminate their At The Marketing Offering Agreement dated September 18, 2023. This agreement was for an at-the-market equity distribution program. The termination will be effective on March 6, 2024. Additionally, AMPE filed a post-effective amendment to withdraw and remove any unsold or unissued securities under its Registration Statement, including shares covered by the at-the-market offering agreement.
February 28, 2024 | 8:51 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Ampio Pharmaceuticals terminates its at-the-market equity distribution agreement with H.C. Wainwright & Co., effective March 6, 2024, and withdraws unsold securities from its registration statement.
The termination of the at-the-market equity distribution agreement and the withdrawal of unsold securities could indicate a strategic shift or financial restructuring for Ampio Pharmaceuticals. However, without further details on the reasons behind these actions or their financial implications, the immediate impact on AMPE's stock price is uncertain, hence a neutral score. The high relevance is due to the direct involvement of AMPE in these actions, and the importance is significant as it pertains to the company's financial strategies and equity management.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100